Only you can determine what fits your situation
Zepbound (tirzepatide) - This dual-action medication targets both GLP-1 and GIP receptors, achieving remarkable results with up to 22.5% weight loss in clinical studies
Calanna S, Christensen M, Holst JJ, Laferrre B, Gluud LL, Vilsbll T, et al
This slow increase allows your body to adapt to the medication and helps manage common gastrointestinal side effects
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Use GoodRx only if manufacturer programs are unavailable
